General Information of Disease (ID: DIS1CYA2)

Disease Name Convulsion
Disease Class 8A61-8A6Z: Epilepsy/seizure
Definition
Disorders characterized by recurrent TICS that may interfere with speech and other activities. Tics are sudden, rapid, nonrhythmic, stereotyped motor movements or vocalizations which may be exacerbated by stress and are generally attenuated during absorbing activities. Tic disorders are distinguished from conditions which feature other types of abnormal movements that may accompany another another condition. (From DSM-IV, 1994)
Disease Hierarchy
DISLR2HH: Specific developmental disorder
DIS1CYA2: Convulsion
ICD Code
ICD-11
ICD-11: 8A68.Z
ICD-9
ICD-9: 780.3
Expand ICD-11
'8A68.Z
Expand ICD-9
780.3
Disease Identifiers
MONDO ID
MONDO_0002420
UMLS CUI
C2169806
MedGen ID
853666
HPO ID
HP:0100033

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anidulafungin DM8QM5U Approved Small molecular drug [1]
Lacosamide DMVM6QR Approved Small molecular drug [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CI-966 DM8T2KA Phase 1 Small molecular drug [3]
GP-3269 DM035LO Phase 1 NA [4]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 3 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
YM-90K DMWRT4L Discontinued in Phase 2 Small molecular drug [5]
Imepitoin DM8OYZB Discontinued in Phase 1 Small molecular drug [6]
SORETOLIDE DMTDLHG Terminated Small molecular drug [7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 2 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
HCN4 TTQP04A Strong Genetic Variation [8]
PRKCI TTWJTHX Strong Biomarker [9]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
GNA13 OTVDL515 Limited Biomarker [10]
ECT2 OTQDUCT6 Strong Biomarker [9]
KCNE1 OTZNQUW9 Strong Genetic Variation [8]
PNKD OT6G9UXN Strong Biomarker [11]
------------------------------------------------------------------------------------

References

1 Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7472).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4612).
4 Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002155)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008368)
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002789)
8 The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease.Biochem Biophys Res Commun. 2019 Oct 29;519(1):141-147. doi: 10.1016/j.bbrc.2019.08.150. Epub 2019 Aug 31.
9 PKC maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.Mol Cancer Res. 2013 Dec;11(12):1624-35. doi: 10.1158/1541-7786.MCR-13-0371-T. Epub 2013 Oct 30.
10 GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers.Oncogene. 2018 Mar;37(10):1340-1353. doi: 10.1038/s41388-017-0038-6. Epub 2017 Dec 19.
11 The PNKD gene is associated with Tourette Disorder or Tic disorder in a multiplex family. Mol Psychiatry. 2018 Jun;23(6):1487-1495. doi: 10.1038/mp.2017.179. Epub 2017 Sep 12.